{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yunn NO"],"funding":["National Research Foundation of Korea (NRF)","National Research Foundation of Korea"],"pagination":["531-541"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9076861"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["54(4)"],"pubmed_abstract":["Aptamers are widely used as binders that interact with targets with high affinity or as inhibitors of the function of target molecules. However, they have also been used to modulate target protein function, which they achieve by activating the target or stabilizing its conformation. Here, we report a unique aptamer modulator of the insulin receptor (IR), IR-A62. Alone, IR-A62 acts as a biased agonist that preferentially induces Y1150 monophosphorylation of IR. However, when administered alongside insulin, IR-A62 shows variable binding cooperativity depending on the ligand concentration. At low concentrations, IR-A62 acts as a positive allosteric modulator (PAM) agonist that enhances insulin binding, but at high concentrations, it acts as a negative allosteric modulator (NAM) agonist that c"],"journal":["Experimental & molecular medicine"],"pubmed_title":["An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration."],"pmcid":["PMC9076861"],"funding_grant_id":["2017M3A9F6029753","2018R1D1A1B07047714"],"pubmed_authors":["Lee HS","Shin E","Oh EJ","Yunn NO","Park M","Jin SY","Lee J","Lee JWY","Kim Y","Ryu SH","Park S","Bae SS"],"additional_accession":[]},"is_claimable":false,"name":"An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration.","description":"Aptamers are widely used as binders that interact with targets with high affinity or as inhibitors of the function of target molecules. However, they have also been used to modulate target protein function, which they achieve by activating the target or stabilizing its conformation. Here, we report a unique aptamer modulator of the insulin receptor (IR), IR-A62. Alone, IR-A62 acts as a biased agonist that preferentially induces Y1150 monophosphorylation of IR. However, when administered alongside insulin, IR-A62 shows variable binding cooperativity depending on the ligand concentration. At low concentrations, IR-A62 acts as a positive allosteric modulator (PAM) agonist that enhances insulin binding, but at high concentrations, it acts as a negative allosteric modulator (NAM) agonist that c","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-04T14:42:00.119Z","creation":"2025-02-18T23:19:17.074Z"},"accession":"S-EPMC9076861","cross_references":{"pubmed":["35478209"],"doi":["10.1038/s12276-022-00760-w"]}}